Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Current Leases (2022 - 2025)

Historic Current Leases for NewAmsterdam Pharma (NAMS) over the last 4 years, with Q3 2025 value amounting to $181000.0.

  • NewAmsterdam Pharma's Current Leases fell 2458.33% to $181000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $181000.0, marking a year-over-year decrease of 2458.33%. This contributed to the annual value of $246000.0 for FY2024, which is 31000.0% up from last year.
  • NewAmsterdam Pharma's Current Leases amounted to $181000.0 in Q3 2025, which was down 2458.33% from $225000.0 recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma's Current Leases registered a high of $252000.0 during Q1 2025, and its lowest value of $43000.0 during Q1 2024.
  • For the 4-year period, NewAmsterdam Pharma's Current Leases averaged around $171583.9, with its median value being $225000.0 (2025).
  • The largest annual percentage gain for NewAmsterdam Pharma's Current Leases in the last 5 years was 48604.65% (2025), contrasted with its biggest fall of 2458.33% (2025).
  • Quarter analysis of 4 years shows NewAmsterdam Pharma's Current Leases stood at $63255.3 in 2022, then dropped by 5.15% to $60000.0 in 2023, then skyrocketed by 310.0% to $246000.0 in 2024, then dropped by 26.42% to $181000.0 in 2025.
  • Its last three reported values are $181000.0 in Q3 2025, $225000.0 for Q2 2025, and $252000.0 during Q1 2025.